Skip to content

DMT: all studies

Page 22 of 160: studies 211 to 220 of 1,593, newest first. Back to the DMT overview

Research

5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?

Psychopharmacology December 11, 2023 Haley Maria Dourron, Charles D. Nichols, Otto Simonsson et al. 23 citations

5-MeO-DMT is a tryptamine being developed as a potential antidepressant that may display a distinct therapeutic mechanism due to its unique pharmacology and subjective effects compared to typical psychedelics. In this article, we parallel the relatively distinct phenomenology and behavioral effects of the acute and post-acute effects of 5-MeO-DMT to those induced by epileptiform activity,...

DOI: 10.1007/s00213-023-06517-1 (opens in new tab) Full text (opens in new tab) 5-ht1a receptors Flashbacks Seizures Psychedelics hallucinogens +7

N, N-dimethyltryptamine forms oxygenated metabolites via CYP2D6 - an in vitro investigation.

Xenobiotica December 1, 2023 Emma Eckernäs, Alicia Macan-Schönleben, Moa Andresen-Bergström et al. 6 citations

N, N-dimethyltryptamine (DMT) is a psychedelic compound that has shown potential in the treatment of depression. Aside from the primary role of monoamine oxidase A (MAO-A) in DMT metabolism, the metabolic pathways are poorly understood. Increasing this understanding is an essential aspect of ensuring safe and efficacious use of DMT.This work aimed to investigate the cytochrome 450 (CYP)...

DOI: 10.1080/00498254.2023.2278488 (opens in new tab) Full text (opens in new tab) N n-dimethyltryptamine Cytochrome p450 Human liver microsomes In vitro metabolism +6

5-MeO-DMT for post-traumatic stress disorder: a real-world longitudinal case study

Frontiers in Psychiatry November 23, 2023 Anya Ragnhildstveit, Ryan Khan, Paul Seli et al. 17 citations

Psychedelic therapy is, arguably, the next frontier in psychiatry. It offers a radical alternative to longstanding, mainstays of treatment, while exciting a paradigm shift in translational science and drug discovery. There is particular interest in 5-methoxy- N,N -dimethyltryptamine (5-MeO-DMT)—a serotonergic psychedelic—as a novel, fast-acting therapeutic. Yet, few studies have directly...

DOI: 10.3389/fpsyt.2023.1271152 (opens in new tab) Adverse effect Psychopathology Clinical psychology

A mechanistic insight for the biosynthesis of N,N-dimethyltryptamine: An ONIOM theoretical approach.

Biochemical and Biophysical Research Communications October 20, 2023 Lucas Pinheiro Coutinho, Sérgio Ruschi Bergamachi Silva, Pedro de Lima-Neto et al. 3 citations

Psychoactive natural products are potent serotonergic agonists capable of modulating brain functions such as memory and cognition. These substances have shown therapeutic potential for treating various mental disorders. The fact that N,N-dimethyltryptamine (DMT) is produced endogenously in several plants and animals, including humans, makes it particularly attractive. As an amino acid-derived...

DOI: 10.1016/j.bbrc.2023.08.043 (opens in new tab) Full text (opens in new tab) Mechanism N,N-Dimethyltryptamine DMT Oniom Psychoactives +4

THE AYAHUASCA’S PSYCHEDELIC COMPONENT DMT POTENTIATES NEURITOGENESIS IN PC12 CELLS

IBRO Neuroscience Reports October 1, 2023 Mariana Pazos, Ignacio Carrera, Giselle Prunell 1 citation

Ayahuasca is a psychedelic beverage originally from the Amazon rainforest used in different shamanic settings for a variety of medicinal, spiritual, and cultural purposes. It is prepared by decoction of the vine Banisteriopsis caapi, source of β-carboline alkaloids, and, Psychotria viridis containing the classic psychedelic N,N-dimethyltryptamine (DMT). As part of the “renaissance of...

DOI: 10.1016/j.ibneur.2023.08.605 (opens in new tab) Ayahuasca Component thermodynamics Mura Hallucinogen

Optimized infusion rates for N,N-dimethyltryptamine to achieve a target psychedelic intensity based on a modeling and simulation framework.

CPT: Pharmacometrics & Systems Pharmacology October 1, 2023 Emma Eckernäs, Jeroen Koomen, Christopher Timmermann et al. 1 citation

N,N-dimethyltryptamine (DMT) is a psychedelic compound that is being studied as a therapeutic option in various psychiatric disorders. Due to its short half-life, continuous infusion of DMT has been proposed to extend the psychedelic experience and potential therapeutic effects. The primary aim of this work was to design an infusion protocol for DMT based on a desired level of psychedelic...

DOI: 10.1002/psp4.13037 (opens in new tab) Full text (opens in new tab) Psychedelic-therapy DMT-Research Clinical-protocols Pharmacology +1

Molecular Docking, MM-GBSA, and Molecular Dynamics Approach: 5-MeO-DMT Analogues as Potential Antidepressants.

Archives of Razi Institute October 1, 2023 Rajagopal Kalirajan, Khare Rishabh, Jupudi Srikanth et al.

Since depression is a common mental illness affecting an estimated 5% of people worldwide, investigators are encouraged to develop effective antidepressants. According to the monoamine-deficiency hypothesis, the underlying pathophysiology of depression is a deficiency of some neurotransmitters (serotonin, norepinephrine, or dopamine) in the central nervous system. The neurotransmitter serotonin...

Discovery and In Vitro Characterization of SPL028: Deuterated N,N-Dimethyltryptamine.

ACS Medicinal Chemistry Letters September 14, 2023 Marie Layzell, Peter Rands, Meghan Good et al. 6 citations

The psychedelic N,N- dimethyltryptamine (DMT) is in clinical development for the treatment of major depressive disorder. However, when administered via intravenous infusion, its effects are short-lived due to rapid clearance. Here we describe the synthesis of deuterated analogues of DMT with the aim of prolonging the half-life and decreasing the clearance rate while maintaining similar...

DOI: 10.1021/acsmedchemlett.3c00143 (opens in new tab) Full text (opens in new tab) Psychedelics Drug development Mental health treatment Pharmaceutical research

Synthetic studies toward the marine alkaloid convolutindole A, a structurally remarkable derivative of the hallucinogen N,N-Dimethyltryptamine (DMT)

Tetrahedron Letters September 13, 2023 Karen Ichikawa, Jessica C. Neville, Yihan Yu et al. 3 citations

Herein we report the results of a synthetic strategy toward the marine alkaloid convolutindole A, a structurally remarkable derivative of the hallucinogen N,N-dimethyltryptamine (DMT). While attempts to forge an advanced tryptamine intermediate using the Fischer reaction were unsuccessful, an iterative C-H functionalisation strategy proved more fruitful. Subjecting 6-bromoindole to an...

Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico.

The American Journal of Drug and Alcohol Abuse September 3, 2023 Alan Kooi Davis, Yitong Xin, Nathan D. Sepeda et al. 29 citations

Background: Research in psychedelic medicine has focused primarily on civilian populations. Further study is needed to understand whether these treatments are effective for Veteran populations.Objectives: Here, we examine the effectiveness of psychedelic-assisted therapy among trauma-exposed Special Operations Forces Veterans (SOFV) seeking treatment for cognitive and mental health problems in...